Insulet (PODD) Long-Term Investments (2017 - 2023)

Insulet posted quarterly Long-Term Investments of $2.0 million for Q2 2023, up 300.0% on a QoQ basis from $500000.0 in Q3 2020.

Insulet (PODD) has 5 years of Long-Term Investments data on file, last reported at $2.0 million in Q2 2023.

For the quarter ending Q2 2023, Long-Term Investments changed N/A year-over-year to $2.0 million; the trailing twelve-month figure through Jun 2023 stood at $2.0 million (changed N/A YoY), and the FY2019 full-year result was $58.4 million, down 58.52% from the prior year.
Long-Term Investments for Q2 2023 stood at $2.0 million, up from $500000.0 in the prior quarter.
Across five years, Long-Term Investments topped out at $76.8 million in Q1 2019 and bottomed at $500000.0 in Q3 2020.
The 3-year median for Long-Term Investments is $44.7 million (2019), against an average of $39.5 million.
Peak annual rise in Long-Term Investments reached 20.82% in 2020, while the deepest fall reached 98.39% in 2020.
A 3-year view of Long-Term Investments shows it stood at $58.4 million in 2019, then tumbled by 99.14% to $500000.0 in 2020, then surged by 300.0% to $2.0 million in 2023.
The last three Long-Term Investments figures came in at $2.0 million (Q2 2023), $500000.0 (Q3 2020), and $23.5 million (Q2 2020), per Business Quant data.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Abbott Laboratories	152.82 Bn	146.17 Bn	6.27 Bn	1.09 Bn
2	Stryker	115.07 Bn	112.19 Bn	3.81 Bn	-
3	Medtronic	95.25 Bn	87.08 Bn	5.76 Bn	-
4	Boston Scientific	71.38 Bn	70.17 Bn	3.61 Bn	-
5	Edwards Lifesciences	51.08 Bn	47.41 Bn	1.29 Bn	285.60 Mn
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	166.25 Mn
7	Dexcom	28.84 Bn	27.72 Bn	750.30 Mn	-
8	GE HealthCare Technologies	28.56 Bn	26.49 Bn	1.98 Bn	-
9	Steris	20.71 Bn	20.30 Bn	697.10 Mn	-
10	Insulet	10.37 Bn	9.89 Bn	529.10 Mn	-

Download Data 🔒